Category - Developments

Developments

Anavex reports Phase 2a efficacy data in AD

Anavex Life Sciences (NASDAQ:AVXL) announced efficacy data through 31 weeks from the ongoing ANAVEX 2-73 Phase 2a study in mild-to-moderate Alzheimer’s patients at the Alzheimer’s Association International Conference in...

July 27, 2016

Developments

Avivagen, UNAHCO register OxC-beta in Philippines

Avivagen (TSX-V:VIV) and UNAHCO have registered OxC-beta Livestock as an imported livestock feed additive, authorizing its use in all species in the Philippines. UNAHCO is a feed and veterinary unit of Unilab, the...

July 27, 2016

Developments

Tandem expands pediatric indication of insulin pump

Tandem Diabetes Care (NASDAQ:TNDM) received FDA clearance of an expanded pediatric indication for the t:slim Insulin Pump, lowering its use to children age 6 and older from children age 12 and older. The t:slim Pump is...

July 26, 2016

Developments

Viking reports positive POC study in X-ALD

Viking Therapeutics (NASDAQ:VKTX) announced positive top-line results from a proof-of-concept study of VK0214 in a mouse model of X-linked adrenoleukodystrophy (X-ALD). The results showed that VK0214 rapidly reduced...

July 26, 2016

Developments

BioLight’s CellDetect posts positive results in prostate cancer

BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology. The study successfully...

July 26, 2016

Developments

Ocular Therapeutix gets complete response letter

Ocular Therapeutix (NASDAQ:OCUL) received a complete response letter (CRL) from the FDA about its NDA for DEXTENZA for intracanalicular use in the treatment of ocular pain occurring after ophthalmic surgery. Concerns...

July 25, 2016

Developments

Anavex presents safety data in AD

Anavex Life Sciences (NASDAQ:AVXL) presented safety data for its ANAVEX 2-73 drug candidate at the Alzheimer’s Association International Conference 2016 in Toronto. Data presented in a poster highlights the evaluation...

July 25, 2016

Developments

JAMA article points to effectiveness of Titan’s buprenorphine implant

A randomized clinical trial reported in the current issue of the Journal of the American Medical Association found that Titan Pharmaceuticals’ (NASDAQ:TTNP) six-month buprenorphine implant, known as Probuphine, may be...

July 19, 2016

Developments

ProMIS in new program to identify ALS targets

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein TDP43, which is implicated in the development of amyotrophic lateral sclerosis (ALS) and...

July 19, 2016

Developments

Academic centers, companies launch Mass. AZ R&D center

The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading BioPharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) to find...

July 15, 2016

Category - Developments

Subscribe